NCT01114230
Completed
Phase 1
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-16M8F Monotherapy in Subjects With Advanced Renal Cell Carcinoma
Overview
- Phase
- Phase 1
- Intervention
- AGS-16M8F
- Conditions
- Renal Cell Carcinoma
- Sponsor
- Astellas Pharma Inc
- Enrollment
- 26
- Locations
- 3
- Primary Endpoint
- Safety assessed by recording adverse events, vital signs and laboratory assessments
- Status
- Completed
- Last Updated
- 13 years ago
Overview
Brief Summary
The purpose of this dose escalation study is to examine the safety and pharmacokinetics (PK) of AGS-16M8F administered in subjects with advanced renal cell carcinoma.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologic or cytologic diagnosis (recent or remote) of metastatic renal cell carcinoma (including papillary, clear cell, and excluding transitional cell types) that is not amenable to cure by surgery or other means.
- •Non-measurable or measurable disease according to Response Criteria for Solid Tumors (RECIST Version 1.1)
- •Eastern Cooperative Group (ECOG) performance status of 0-1
- •Negative pregnancy test (women of childbearing potential)
- •Hematologic function, as follows:
- •Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- •Platelet count ≥ 100 x 109/L
- •Hemoglobin ≥ 9 g/dL (transfusions are allowed)
- •Renal function, as follows:
- •creatinine ≤ 1.5 x upper limit of normal (ULN), or calculated glomerular filtration rate (GFR) \> 50 mL/min if creatinine \> 1.5x ULN
Exclusion Criteria
- •Past or present documented central nervous system (CNS) tumor or CNS metastasis
- •Use of any investigational drug (including marketed drugs not approved for this indication) within 4 weeks prior to screening
- •History of thromboembolic events and bleeding disorders ≤ 3 months (e.g., DVT or PE)
- •Active angina or Class III or IV Congestive Heart Failure (New York Heart Association CHF Functional Classification System) or clinically significant cardiac disease within 12 months of study enrollment, including myocardial infarction, unstable angina, grade 2 or greater peripheral vascular disease, congestive heart failure, uncontrolled hypertension, or arrythmias not controlled by outpatient medication
- •Major surgery (that requires general anesthesia) within 4 weeks of study enrollment
- •Women who are pregnant (confirmed by positive pregnancy test) or lactating
- •Known positive test for human immunodeficiency virus (HIV), hepatitis C, or hepatitis B surface antigen
- •Active infection requiring treatment with systemic (intravenous or oral) anti-infectives (antibiotic, antifungal, or antiviral agent) within 72 hours of screening
Arms & Interventions
Dose Level 1
Intervention: AGS-16M8F
Dose Level 2
Intervention: AGS-16M8F
Dose Level 3
Intervention: AGS-16M8F
Dose Level 4
Intervention: AGS-16M8F
Dose Level 5
Intervention: AGS-16M8F
Dose Level 6
Intervention: AGS-16M8F
Dose Level 7
Intervention: AGS-16M8F
Dose Level 8
Intervention: AGS-16M8F
Dose Level 9
Intervention: AGS-16M8F
Outcomes
Primary Outcomes
Safety assessed by recording adverse events, vital signs and laboratory assessments
Time Frame: For 12 weeks during treatment period and up to 4 weeks follow up
Pharmacokinetic variables assessment through analysis of blood samples
Time Frame: Up to day 15 for cycle 1 and cycle 4 and pre-dose for cycles 2 and 3; every 3 weeks during the second 12 weeks of treatment; and if subject continues on study drug, every 12 weeks thereafter
Secondary Outcomes
- Incidence of anti-AGS-16M8F antibody formation(Baseline; up to day 64 during the first 12 weeks; and if subject continues on study drug, every 3 weeks during the second 12 weeks of treatment and every 12 weeks thereafter)
- Incidence of Tumor Response (complete or partial response)(Baseline and every 12 weeks while on study drug)
Study Sites (3)
Loading locations...
Similar Trials
Completed
Phase 1
MGD009/MGA012 Combination in Relapsed/Refractory CancerAdvanced Solid TumorsNCT03406949MacroGenics25
Completed
Phase 1
A Safety Study of SGN-CD19A for B-Cell LymphomaBurkitt LymphomaLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellPrecursor B-cell Lymphoblastic Leukemia-LymphomaNCT01786135Seagen Inc.64
Completed
Phase 1
A Safety Study of SGN-CD19A for Leukemia and LymphomaBurkitt LymphomaPrecursor B-cell Lymphoblastic Leukemia-LymphomaNCT01786096Seagen Inc.92
Withdrawn
Phase 1
Study of Select Combinations in Adults With MyelofibrosisPrimary MyelofibrosisMyelofibrosisPMFPost-Essential Thrombocythemia MyelofibrosisPost-Polycythemia Vera MyelofibrosisNCT04283526Novartis Pharmaceuticals
Completed
Phase 1
A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic CancerMetastatic Pancreatic CancerNCT02734160Eli Lilly and Company37